Background Several copy number variants (CNVs) are associated with a high risk of neurodevelopmental and psychiatric disorders (referred to as ND-CNVs). We aimed to characterise the effect of ND-CNVs on childhood development and investigate whether different ND-CNVs lead to distinct and specific patterns of cognitive and behavioural outcomes.
Introduction
The advent of microarray technology has heralded a new era for understanding the clinical genetics of neuropsychiatric disorders. A notable finding has been the implication of copy number variants (CNVs) in these disorders, 1 including intellectual disability, autism spectrum disorders, and schizophrenia. [2] [3] [4] CNVs are submicroscopic deletions or duplications within the genome that are greater than 1000 base-pairs in size 5 and several loci have been identified where CNVs recur with sufficient frequency in the population to be associated with neurodevelopmental and psychiatric outcomes; these high-risk CNVs will hereafter be referred to as ND-CNVs. Recurrent ND-CNVs are individually rare, but collectively pathogenic ND-CNVs have been implicated in approximately 15% of patients with neurodevelopmental disability. 6 Although these ND-CNVs are strongly associated with neurodevelop mental and psychiatric disorders, they have incomplete penetrance and have a high degree of pleiotropy, conferring risk for a broad range of psychiatric disorders, cognitive deficits, and medical and physical comorbidities across the lifespan. [7] [8] [9] [10] Current understanding of genotype-phenotype associations is hampered by a lack of studies with cross-CNV comparisons.
11 Therefore, the extent to which pheno typic findings for different genotypes can be compared across studies, when only one genotype is often assessed per study, is unclear because differences in findings could be due to variation in sample sizes, ascertainment methods, and phenotyping batteries. Increasing use of microarray screening in the assessment of children with neurodevelopmental delays is leading to an increase in the diagnosis of ND-CNVs at medical genetics clinics, yet information on long-term neuropsychiatric prognoses is scarce. Understanding of whether different genotypes are associated with specific neuropsychiatric, cognitive, and other phenotypes is needed. We posit four different models of potential genotype-phenotype associations, as illustrated in figure 1 . In model 1, the null model, the phenotypic profile does not differ between genotypes. In model 2, phenotypic differences are qualitative in nature, such that each ND-CNV is associated with a distinct phenotype due to the specific genes involved. In model 3, phenotypic differences are quantitative in nature: all ND-CNVs affect the same range of outcomes but differ from each other in magnitude of impairment. Model 4 is a combination of models 2 and 3. Support for model 2 (qualitative differences model) exists in the autism field, in which the disorder is hypothesised to be dissociable because of distinct genetic under pinnings, 12, 13 with some researchers using the term autisms.
14 Model 3 (the quantitative differences model) is supported by findings that genes across ND-CNVs affect shared pathways, leading to outcomes such as cognitive impairment 15 and increased risk of schizophrenia, 16 indicating that common mechanisms act across loci. Importantly, variability in phenotypic outcomes will also be shaped by incomplete penetrance, 8 lifecourse develop mental stage, 17 genetic context, including polygenic risk 18 and additional mutations, 19, 20 and environmental exposures. 21 The Intellectual Disability and Mental Health: Assessing the Genomic Impact on Neurodevelopment (IMAGINE-ID) consortium has recruited a cohort of children with ND-CNVs, creating a lasting resource for research into intellectual disability, genotype, and mental
Research in context
Evidence before this study Several copy number variants (CNVs) have been associated with high risk of development of child and adult neuropsychiatric disorders. Increasingly, young children with developmental delays referred for genetic testing are being diagnosed with neurodevelopmental and psychiatric risk CNVs (referred to as ND-CNVs hereafter). Whether different genotypes are associated with specific cognitive and behavioural phenotypes or whether these outcomes are non-specific is still unclear. We searched PubMed for publications in English from database inception until Jan 10, 2019 , that investigated the association between CNVs and cognitive and behavioural outcomes using the search terms "CNV", "genomics", "1q21.1", "2p16.3", "NRXN1", "9q34", "Kleefstra Syndrome", "15q11.2", "15q13.3", "16p11.2", "22q11.2", "psychiatry", and "cognition". Preliminary studies have indicated that deletions and duplications at the same loci might differ in cognitive and behavioural phenotypes; however, to date, few studies have contrasted the phenotypes of ND-CNVs across several loci on a range of cognitive and behavioural domains.
Added value of this study
We found that young people with an ND-CNV were at considerably increased risk of neuropsychiatric disorders and impairments across a range of neurodevelopmental, psychopathological, cognitive, social, sleep, and motor traits compared with sibling controls. In ND-CNV carriers, comparisons between genotypes indicated moderate quantitative and qualitative differences in overall phenotypic profile, with evidence that severity of impairment was similar across all genotypes for some traits (eg, mood problems, sleep impairments, peer problems, and sustained attention), whereas for other traits we found evidence of genotype-specific effects on severity (eg, intelligence quotient, spatial planning, processing speed, subclinical psychotic experiences, autism spectrum disorder traits, motor coordination, and total psychiatric symptomatology-particularly anxiety, attention-deficit hyperactivity disorder, and conduct-related traits). However, the proportion of variance explained by genotype was low, at approximately 5-20% depending on the trait, indicating that overall ND-CNVs lead to similar neurodevelopmental outcomes. Some phenotypic outcomes were found to be associated with age so genotype-phenotype associations should be viewed with a developmental perspective.
Implications of all the available evidence
Children who are ND-CNV carriers are a patient group that warrants clinical and educational attention for a broad range of cognitive and behavioural impairments. This group of young people could benefit from the development of a general care pathway, to which genotype-specific recommendations can be added as needed. The association between genotype and neurodevelopmental phenotype is complex and future research will need to take a global systems approach and not focus narrowly on single phenotypes.
For IMAGINE-ID data see http://imagine-id.org/healthcareprofessionals/datasharing/ health. Here we report on findings from the deep phenotyping component of the IMAGINE-ID study. First, we characterised the effect of recurrent ND-CNVs on child development by comparing the cognitive and behavioural traits of ND-CNV carriers with sibling controls. Second, we assessed the phenotypic differences between ND-CNV genotypes and determined whether these were qualitative or quantitative in nature. Finally, we established the extent to which cognitive and behavioural traits, and other outcomes were affected by sex and age.
Methods

Study design and population
In this prospective case-control cohort study, we used data from the IMAGINE-ID cohort, which recruits individuals aged 4 years and older with genomic variants that have been associated with neurodevelopmental problems. The IMAGINE-ID cohort has two levels, broad online phenotyping on over 2100 individuals (not focused on in this Article) and deep phenotyping on a subgroup (data presented here). Participants are recruited on the basis of genotype via the UK National Health Service (NHS) medical genetic clinic network, in which microarray results can be accessed, and patients can be retrospectively and prospectively invited to take part in research studies. NHS patients were also recruited via support groups, including Unique, Max Appeal, and other groups on social media. The IMAGINE-ID study comprises two components. First, parents with a child aged 4 years or older with a pathogenic CNV or single nucleotide variant were invited to complete an online assessment of broad phenotyping (>2100 have been completed to date, the results of which will be reported elsewhere). Second, from this pool, families with a child with one of a set of specific, recurrent ND-CNVs were approached for a deep phenotyping home-based assessment and here we report on this sample. The specific loci were 1q21.1 (proximal and Figure 1 : Models of genotype-phenotype associations Each cell represents the Z score performance for a neuropsychiatric domain. In model 1, no phenotypic differences exist between genotypes. In model 2, qualitative differences exist, such that the neuropsychiatric profile differs by genotype, but no quantitative differences exist. Each genotype has the same overall severity of impairment, but the distribution across phenotypic traits is different-eg, for genotype 1, phenotypes 2 and 6 are most severely affected, whereas for genotype 3, phenotypes 2 and 10 are most severely affected. In model 3, quantitative differences exist because each genotype differs in average extent of impairment; however, no qualitative differences exist in phenotypic profile within each genotype. In model 4, both quantitative and qualitative differences in neuropsychiatric profile exist. P h e n o t y p e 1
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Model 2 Z score P h e n o t y p e 2 P h e n o t y p e 3 P h e n o t y p e 4 P h e n o t y p e 5 P h e n o t y p e 6 P h e n o t y p e 7 P h e n o t y p e 8 P h e n o t y p e 9 P h e n o t y p e 1 0 P h e n o t y p e 1 P h e n o t y p e 2 P h e n o t y p e 3 P h e n o t y p e 4 P h e n o t y p e 5 P h e n o t y p e 6 P h e n o t y p e 7 P h e n o t y p e 8 P h e n o t y p e 9 P h e n o t y p e 1 0 P h e n o t y p e 1 P h e n o t y p e 2 P h e n o t y p e 3 P h e n o t y p e 4 P h e n o t y p e 5 P h e n o t y p e 6 P h e n o t y p e 7 P h e n o t y p e 8 P h e n o t y p e 9 P h e n o t y p e 1 0 P h e n o t y p e 1 P h e n o t y p e 2 P h e n o t y p e 3 P h e n o t y p e 4 P h e n o t y p e 5 P h e n o t y p e 6 P h e n o t y p e 7 P h e n o t y p e 8 P h e n o t y p e 9 P h e n o t y p e 1 0 2 (further details are in the appendix). These recurrent ND-CNVs were selected because they are robustly associated with intellectual disability and neuropsychiatric phenotypes, [22] [23] [24] including schizophrenia and autism spectrum disorder and are frequently diagnosed in medical genetic clinics. We approached families to take part if the child with the ND-CNV was aged 6-19 years (the age range in which our assessment battery operates) and if the presence of the ND-CNV was confirmed from accessing medical records. From NHS medical genetics clinic records, Cardiff Univeristy Division of Psychological Medicine and Clinical Neurosciences laboratory genotyping, or both, we could ascertain the locus, copy number (deletion or duplication), variant origin (de novo or inherited), and presence of additional ND-CNVs of interest for each child. Children with a known diagnosis of more than one ND-CNV were excluded from further analyses. In each family, a sibling without the ND-CNV (sibling control) and closest in age to the index child was also invited to take part. Availability of microarray results and medical records allowed us to confirm the absence of ND-CNVs in control siblings where possible; however, if data were not available for control siblings they were still included in analyses.
Written informed consent was gained from primary carers and participants. The protocol was approved by the NHS London Queen Square research ethics committee, and is available online.
Assessments
We measured 25 quantitative cognitive and behavioural traits and five composite scores using a multi-informant approach. Additionally, we derived categorical psychiatric diagnoses. Children were assessed by experienced research psychologists (including SJRAC). Assessments were done in the participant's home, which had the advantage of maximised accessibility to the study and decreased bias against participants who might experience difficulty travelling to a research clinic. Furthermore, participants could be assessed in a familiar setting where they were less likely to be anxious and more likely to engage with the assessments than if they were in unfamiliar surroundings.
We assessed cognition via direct assessment of the child. Intelligence quotient (IQ) was assessed using the Wechsler Abbreviated Scale of Intelligence, 25 from which scores for non-verbal reasoning, perceptual organisation, verbal knowledge, and verbal reasoning, and full scale IQ, performance IQ, and verbal IQ composite scores were derived. Set-shifting ability was assessed using the Wisconsin Card Sorting Test. 26 We used the Cambridge Neuropsychological Test Automated Battery (Cambridge Cognition, Cambridge, UK) to assess spatial working memory, spatial planning, sustained attention, and processing speed.
For psychopathology and functioning, we used the Child and Adolescent Psychiatric Assessment (CAPA) 27 caregiverreported interview to derive categorical diagnoses, a total CAPA symptom count composite score, and the following symptom subscales: attention-deficit hyperactivity disorder (ADHD), anxiety, mood, obsessive-compulsive disorder (OCD), oppositional defiant disorder, and problems with sleep. We used the child-reported CAPA to assess subclinical psychotic experiences. We made voice recordings of interviews, and diagnoses were confirmed via a consensus meeting led by a child psychiatrist.
Research psychologists who did the home visits (including SJRAC) assessed general and social functioning using the Children's Global Assessment Scale 28 and the Social and Occupational Functioning Assessment Scale. 29 We assessed autism spectrum disorder traits via caregiver report using the Social Communication Questionnaire. 30 We assessed impairment of motor coordination by caregiver report using the Developmental Coordination Disorder Questionnaire. 31 The caregiver and teacher of the child completed the Strengths and Difficulties Questionnaire (SDQ), 32 from which we derived conduct, emotional, hyperactivity, peer (quality of peer relationships), and prosocial subscale scores and SDQ total composite score. Full details of assessments are in the appendix.
Outcomes
We had three objectives: first, to assess cognitive and behavioural phenotypes of ND-CNV carriers compared with controls; second, to investigate the qualitative and quantitative differences between different ND-CNVs; and finally, to assess the effect of age and sex on cognitive and behavioural outcomes.
Statistical analysis
For our first objective, for categorical outcome measures, we compared the prevalence of psychiatric disorders between ND-CNV carriers and controls using generalised linear mixed-effects models, with carrier status (ie, carrier vs control), age, and sex as fixed effects, and family as a random effect to take into account that control siblings are related to ND-CNV carriers. For disorders for which no comparative data for controls existed, p values were estimated using Fishers exact test, and should be interpreted cautiously. For continuous outcome measures, we transformed all cognitive and behavioural trait scores and composite scores (ie, full scale IQ, performance IQ, verbal IQ, total CAPA symptom count, and SDQ total score) using the Tukey Ladder of Powers transformation to make the data fit the normal distribution as closely as possible. We then standardised all transformed test scores into Z scores using the mean and SD of the control group as reference-ie, the difference in the individual's score and the mean score for the entire control group was divided by the SD for the control group. We constructed these Z scores so that a See Online for appendix For the IMAGINE-ID study protocol see http://imagine-id. org/wp-content/uploads/2016/ 08/protocol5_0_161213 IMAGINEID.pdf negative score for an ND-CNV carrier denoted a worse outcome. We used linear mixed-effects models with test score as the outcome and carrier status, age, and sex as fixed effects and family as a random effect. We calculated effect sizes using Cohen's d to estimate the standardised difference between ND-CNV carriers and controls, adjusted for age and sex, and scores were categorised by effect size descriptor 33 such that a Cohen's d value of 0·00-0·19 indicates a negligible effect, 0·20-0·49 a small effect, 0·50-0·79 a medium effect, and 0·80 or higher a large effect. To assess the potential effects of intelligence on group differences, we repeated these analyses with full scale IQ as a covariate. To investigate the associations between caregiver-reported and teacher-reported SDQ scores, we did Pearson correlations between the caregiver report and teacher report. An r value closer to 1 indicates greater similarity in caregiver and teacher report.
We did a post-hoc analysis repeating these analyses excluding controls for whom the absence of ND-CNVs had not been confirmed.
For our second objective, to investigate which genotype-phenotype association model (figure 1) best explained our data, we used the Z scores generated for each child with a ND-CNV to calculate the mean Z score across individuals with the same ND-CNV genotype for each trait. We did hierarchical clustering using Ward's method and Euclidean distance to investigate which ND-CNVs, and which cognitive and behavioural phenotypes, clustered together, this process generated a dendrogram.
Our analysis of qualitative and quantitative differences in overall phenotypic profile was based on ranking the mean Z score of each phenotypic trait score for each ND-CNV. In the analysis of qualitative effects, we created a set of phenotype rankings for each ND-CNV (model 2: within each genotype row, phenotype was ranked by phenotypic severity; figure 1). If rank discordance is seen between ND-CNVs, it would suggest that the phenotypic profile for each ND-CNV differs, indicating the presence of qualitative differences. In the analysis of quantitative effects, we created a set of ND-CNV rankings for each phenotype (model 3: within each phenotype column, each ND-CNV was ranked by phenotypic severity; figure 1 ). If rank concordance is seen between phenotypes, it would suggest that ND-CNVs differ in severity across phenotypes, indicating quantitative differences. Notably, these models are not opposing ends of a spectrum, both quantitative and qualitative effects can be present (model 4; figure 1 ). To test for similarities and differences for both qualitative and quantitative effects across ND-CNVs, we assessed rank concordance using Kendall's (F) test and rank discordance using the Friedman (χ²) test. This approach, based on rank concordance, has been used previously to investigate genotype-phenotype associations. 34 To avoid colinearity, we did not include composite scores in the concordance analysis. Furthermore, to test for quantitative effects between ND-CNVs at the level of individual traits, we did an ANCOVA with the test score as the outcome, genotype as the predictor, and sex and age as covariates. We estimated η² from the ANCOVAs done for the quantitative analysis. η² values reflect the proportion of variance in the quantitative trait explained by the predictor. We did the following post-hoc analyses: first, we excluded individuals with ND-CNVs whose profiles stood apart, as indicated by the dendrogram, to check that they were not driving findings; second, we used a new set of rankings based on subcluster scores to confirm that the results were not driven by an overlap between different phenotypic measures. Further details are in the appendix.
For our final objective, to investigate the influence of sex and age on the behavioural and cognitive outcomes of ND-CNV carriers, we estimated η² and standardised β value from the ANCOVAs done for the quantitative analysis. The standardised β values reflect the magnitude and direction of effect of the predictor on phenotypic outcome. For sex, a positive β value indicated that males had a higher score than females, for age a positive β value indicated that the score increased with age.
We did a post-hoc analysis repeating these analyses including family ethnic background and family income effect on genotype, age, and sex. We also did post-hoc interaction analyses to evaluate whether associations between age and phenotypic outcomes differed between ND-CNV carriers and controls.
To correct for multiple testing in all analyses, we applied a Benjamini-Hochberg false discovery rate (FDR) of 0·05 for correction of p values. We did all analyses using R version 3.4.2. This study is registered on the UK Research and Innovation website.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
Between Oct 1, 2014, and Dec 31, 2018, of 2819 children recruited for the IMAGINE-ID study, 274 (10%) children with one of the ND-CNVs of interest were enrolled and took part in detailed assessments. Of the 274 children, 16 (6%) were excluded from analyses because they had more than one of the ND-CNVs. Hence, our study population comprised 258 children with an ND-CNV, with a mean age of 9·7 years [SD 3·1], and of whom 170 (66%) were boys and 88 (34%) were girls. Of the 258 ND-CNV carriers, 59 (23%) had a de-novo variant, 114 (44%) an inherited variant, and for 85 (33%) variant origin was unknown. 85 (33%) participants were duplication carriers and 173 (67%) were deletion carriers. The frequency of each ND-CNV is shown in the appendix. 106 sibling controls were enrolled, with a mean age of 10·9 years (SD 3·0), of whom 55 (52%) were boys and 51 (48%) were girls. Of these controls, we confirmed that 77 (73%) did not have ND-CNVs-with the remaining 29 (27%) not having full genetic confirmation of the absence of ND-CNVs-16 (15%) were from families with an inherited CNV, and 13 (12%) were from families in which the variant origin for the CNV carrier was unknown. All controls were included in the main analysis.
Prevalence of any psychiatric disorder was significantly increased in ND-CNV carriers (186 [80%] of 233 with available data) compared with controls (21% [16 of 75 with available data]; odds ratio [OR] 13·8, 95% CI 7·2-26·3; p=7·79 × 10 -⁷). ND-CNV carriers had significantly increased prevalences of ADHD, oppositional defiant disorder, any anxiety disorder, autism spectrum disorder, and tic disorders compared with controls (table 1) . These results remained significant when we controlled for full scale IQ (data not shown) and after Benjamini-Hochberg FDR correction. Mood disorder, OCD, and subclinical psychotic experiences were present in ND-CNV carriers but the prevalence was not significantly increased compared with controls (table 1) . None of the ND-CNV carriers or controls met criteria for psychotic disorder.
Our linear mixed-effects model analysis found that ND-CNV carriers had significant impairment on all our continuous measures of cognitive and behavioural traits and composite scores compared with controls (table 2, figure 2 ). These results remained significant when full scale IQ was controlled for (data not shown), and after Benjamini-Hochberg FDR correction. Effect sizes measured using Cohen's d varied from 0·27 (95% CI 0·02 to 0·52) for subclinical psychotic experiences to 1·76 (95% CI 1·46 to 2·05) for SDQ caregiver-reported hyperactivity subscale. We found large differences in effect size between ND-CNV carriers and controls for full scale IQ, including performance IQ, verbal IQ, and all comprising subtests; sustained attention; total psychiatric symptom count (CAPA); ADHD CAPA subscale; autism spectrum disorder traits; general and social functioning; motor coordination; total SDQ score (caregiver and teacher reported); and hyperactivity (caregiver and teacher reported), peer (caregiver reported), and prosocial (caregiver reported) SDQ subscales. Most differences remained significant when we compared all deletion carriers with the controls and all the duplications carriers with the controls (appendix; differences between each ND-CNV group and controls in phenotypic outcomes are also in appendix). Findings remained similar when the 29 control siblings for whom we did not have full genetic confirmation of absence of the ND-CNVs under study were excluded (appendix); therefore, all control siblings (n=106) were included in all subsequent analyses. As well as caregivers, teachers reported that ND-CNV carriers scored significantly worse on SDQ total and subscale scores than controls did (table 2, figure 2 ). Teacherreported SDQ scores were moderately correlated to scores reported by caregivers: total SDQ score r=0·470, p=1·35 × 10 -¹¹; SDQ subscale scores, r=0·316 to 0·548; p=5·69 × 10 -¹⁶ to 1·13 × 10 -⁵; full data not shown). In ND-CNV carriers, mean Z score (adjusted for age and sex) on phenotypic traits for each ND-CNV are visualised in figure 3 as a dendrogram, in which distinct profiles are apparent. Regarding phenotypic associations, two clusters can be distinguished: neurodevelopmental traits (eg, hyperactivity, autism spectrum disorder traits, general functioning, motor coordination) and mental health and cognitive comorbidities (eg, verbal knowledge and reasoning, set-shifting and oppositional-defiant disorder; figure 3 ). All genotypes showed evidence of strong impairments in the neurodevelopmental traits cluster, whereas the extent of impairment within the mental health and cognitive comorbidities cluster was weaker and more variable across ND-CNVs (the traits that comprise each cluster are shown in figure 3 , and Z scores for each ND-CNV are in the appendix). We found no strong evidence that deletion variants differed in profile from duplication variants, or that deletions and duplications at the same loci differed in profile ( figure 3) .
In terms of the overall phenotypic profile, we found evidence of both qualitative and quantitative differences Data are n/N, proportion, or odds ratio, with 95% CI in parentheses. Generalised linear mixed-effects models were used with diagnosis as the outcome and carrier status, age and gender as fixed effects and family as a random effect. The total number of carriers and controls for each disorder is not the same as the number enrolled due to missing data. ND-CNV=neuropsychiatric disorder-copy number variant. *Remained significant after Benjamini-Hochberg false discovery rate 0·05 correction. †Because no controls had this disorder, odds ratios could not be estimated; p values were estimated using Fisher's exact test. These findings indicate that although significant quantitative and qualitative differences exist, qualitative and quantitative similarities also exist. We therefore conclude effects for both qualitative and quantitative differences between genotypes are moderate, and overall our data support model 4 ( figure 1 ). We did a post-hoc sensitivity analysis excluding individuals with 9q34.3 deletion or 22q11.2 deletion because the dendrogram (figure 3) indicated their phenotypic profiles stood apart from the other ND-CNVs, which could drive the differences we found. However, excluding these two groups did not change our finding of moderate qualitative and quantitative differences between genotypes, and did not change the hierarchical clustering of traits into neurodevelopmental traits and mental health and cognitive comorbidities (data not shown). We did further sensitivity analysis to confirm that our findings were not driven by one of the two clusters specifically or by an overlap between different phenotypic measures (appendix). We found that moderate qualitative and quantitative differences existed in both the neurodevelopmental traits and the mental health and cognitive comorbidities clusters. Our findings remained the same when analyses were done on a second set of rankings based on subcluster scores, therefore taking account of overlapping correlated phenotypic traits (post-hoc analysis; subclusters were identified from the hierarchical clustering done for figure 3 and are shown in the appendix).
Regarding individual phenotypic traits, we found quantitative differences with genotype predicting approximately 5-20% of variance (η² effect size) in impairment in ND-CNV carriers depending on the specific trait (table 3) . The effect of genotype significantly predicted impairment severity in some traits, including full scale IQ; performance IQ; verbal IQ; all the IQ subtests; spatial planning; processing speed; total CAPA symptom count; anxiety, ADHD, and oppositional defiant disorder CAPA subscales; subclinical psychotic experiences; social functioning; autism spectrum disorder traits; motor coordination; SDQ total score; and conduct, hyperactivity, and prosocial SDQ subscales (table 3) . However, genotype had no significant effect on set-shifting; spatial working memory; sustained attention; mood, OCD, and sleep CAPA subscales; general functioning; and emotional and peer SDQ subscales. For these analyses, p values remained significant after Benjamini-Hochberg FDR 0·05 correction. These findings remained largely the same when we included family ethnic background and family income in the analysis, with genotype explaining 5-21% of variation in phenotypic outcome depending on the trait (appendix). The phenotypic profile of ND-CNV carriers was affected by age (accounting for approximately 0-25% of variance, depending on the trait; notably, only sustained attention was 25·1% and that all other traits were between 0 and about 5%) with deficits in some traits being decreased in older children-eg, the hyperactivity SDQ subscale (β=0·18; p=5·04 × 10 -³), sustained attention (β=0·53; p=1·89 × 10 -¹¹), and higher executive function (set-shifting, β=0·18; p=0·0132; table 3). Deficits in other traits were found to be greater in older children-eg, full scale IQ (β=-0·18; p=3·61 × 10 -³), spatial working memory (β=-0·19; p=7·92 × 10 -³), mood CAPA subscale (β=-0·17; p=0·0105), subclinical psychotic experiences (β=-0·20; p=1·40 × 10 -³), and the peer subscale of the SDQ (β=-0·21; p=1·34 × 10 -³). For the traits we found to be associated with age, we did post-hoc interaction analysis to evaluate whether evidence of differences in the association between age and phenotypic outcome existed between ND-CNV carriers and controls. An interaction between age and group status (ND-CNV carriers vs controls) was found only for the CAPA mood subscale score (p=4·38 × 10 -²), indicating that the difference in mood problems is greater at older ages than younger ages in ND-CNV carriers than in controls. For the other traits (hyperactivity SDQ subscale, spatial working memory, sustained attention, set-shifting, full scale IQ, spatial working memory, subclinical psychotic experiences, and the peer SDQ subscale) no evidence of differential development with age was found between ND-CNV carriers and controls (data not shown). Sex was found to influence phenotypic outcomes in ND-CNV carriers but accounted for little variation (approximately 0-4% depending on the trait). Boys performed worse than girls on the hyperactivity SDQ subscale (β=0·17, p=0·0161), sleep CAPA subscale (β=0·16, p=0·0183), and sustained attention (β=0·18, p=5·35 × 10 -³), but they performed V e r b a l k n o w l e d g e V e r b a l r e a s o n i n g S u s t a i n e d a t t e n t i o n N o n -v e r b a l r e a s o n i n g P e r c e p t u a l o r g a n i s a t i o n S e t -s h i f t i n g S p a t i a l p l a n n i n g better than females on the performance IQ perceptual organisation subtest (β=-0·16, p=6·37 × 10 -³; table 3). For our analyses of the effects of sex and age on phenotypic outcomes, p values remained significant after Benjamini-Hochberg FDR 0·05 correction. Both the age and sex associated analyses remained largely the same when accounting for family ethnic background and family income (post hoc; appendix).
Discussion
To our knowledge, this is the largest study within the CNV literature to compare different phenotypes. Overall, our findings support a model whereby these ND-CNVs have a broadly general effect on phenotypic outcomes, but specific effects can be identified, albeit accounting for a low proportion of variance (approximately 5-20% depending on the trait). Some traits had a similar magnitude of impairment across all genotypes (eg, mood problems, sleep impairment, peer problems, and sustained attention), whereas for other traits evidence supported more genotype-specific patterns (eg, IQ, spatial planning, processing speed, subclinical psychotic experiences, autism spectrum disorder traits, motor coordination, and total psychiatric symptomatology, particularly anxiety, ADHD, and conduct-related traits). Phenotypic differences within ND-CNV carriers were found to be both quantitative and qualitative in nature (ie, model 4, shown in figure 1 ). Hierarchical cluster analysis of phenotypic traits identified two clusters; neurodevelopmental traits that were strongly impaired across CNVs, and mental health and cognitive comorbidities for which the extent of impairment was generally weaker and more variable across the genotypes. ND-CNVs influence biological pathways that affect the risk of developmental impairment and this impairment differs in magnitude by genotype, but the unique gene content of each ND-CNV also appears to mould specific psychiatric, cognitive, and other manifestations. As a group, children with an ND-CNV were found to be at very high risk of developing a psychiatric disorder, with 80% having at least one psychiatric diagnosis. Moreover, using a broad multiinformant approach, we found that ND-CNV carriers were impaired compared with sibling controls across all the psychiatric, neurodevelopmental, psychopathological, cognitive, social, sleep, and motor domains assessed. This patient group clearly warrants clinical and educational attention and intervention. We found ND-CNV carriers to be at increased risk of a range of psychiatric disorders, including ADHD, anxiety disorder, autism spectrum disorder, oppositional defiant disorder, and tic disorder. All the ND-CNV carriers had impairments across all behavioural and cognitive traits measured, and the strongest trait differences found between ND-CNV carriers and controls included autism spectrum disorder traits, hyperactivity on the SDQ subscale, social functioning, and motor coordination. Motor coordination is a domain that has been relatively understudied in the context of ND-CNV carriers, but studies have indicated that it is an antecedent of 35 and indexes psychiatric disorder 36 in ND-CNV carriers. Our teacher-reported measures confirmed that neuropsychiatric impairments were present in school as well as at home, indicating pervasiveness of these impair ments. Our findings of a broad range of impairments are consistent with studies of common polygenic risk 37 and familial risk 38, 39 of psychiatric disorders that found that genetic risk is associated with disrupted childhood neurodevelopment across several domains. The prevalence of psychiatric disorder in control siblings was in line with previous population studies that have used the same instruments as in this study 40, 41 and that have compared ND-CNV carriers to controls. 42, 43 Some previous studies of 22q11.2 deletion carriers have used community controls, but the effect sizes we found when we drew comparisons with sibling controls are broadly similar. 44, 45 The specific effect of CNV genotype accounted for only approximately 5-20% of variation in outcomes depending on the phenotypic trait, indicating that most variance is explained by additional factors. We found that age was a predictor of outcome for several traits, with both ADHD symptoms and deficits in the cognitive measures of sustained attention and set-shifting decreasing with age, whereas IQ deficits, spatial working memory, mood symptoms, subclinical psychotic experiences, and peer problems increased with age. These trends agree with those from general population studies. 40, 46 We found that the increase in mood symptoms with age was greater in ND-CNV carriers than in controls. The other phenotypic traits, although impaired in ND-CNV carriers, showed similar trends with increasing age as in controls. These initial cross-sectional findings show the importance of having a control group when investigating genotypephenotype associations from a developmental viewpoint. 17, 47 These cross-sectional findings warrant longitudinal studies. Although we found differences between the sexes in neurodevelopmental traits previously reported for the general population, 45 the proportion of variance explained by sex was low (<5%). This lack of between-sex difference might reflect the fact that male-to-female ratios for conditions such as autism are decreased in populations with intellectual disability. 49 Further research is required to understand which genetic and environmental factors underlie the remaining, unexplained variation in outcomes.
The high prevalence of psychiatric disorders and the finding that ND-CNV carriers were impaired across all cognitive, motor, and psychopathological measures assessed highlight that children with ND-CNVs require coordinated multidisciplinary care to address a range of psychiatric, psychological, motor coordination, sleep, social, and educational needs. Coordinated care for this genomically defined patient group warrants a step change in current clinical service provision and calls for increased awareness of this new patient group among clinicians and educators. The commonalities we found in clinical outcomes across ND-CNVs suggest that this group could benefit from the development of a dedicated clinical care pathway, which would provide psychoeducation about the broad range of associated risks alongside tailored monitoring of more genotype-specific vulnerabilities. Support and inter vention plans for children with an ND-CNV need to consider the child's behaviour in educational and peer contexts and address behaviour that is exhibited in the home or clinic. The presence of similarities in clinical outcomes also indicates that genomic risk for neurodevelopmental conditions affects shared biological processes that could be targeted for pharmacological intervention. Notably, several ND-CNVs have been linked to synaptic dysfunction. 16 The broad ranging phenotypic outcomes associated with ND-CNVs indicate that genotype-phenotype associations have a complex architecture. Current research efforts that identify direct causal pathways from genotype to psychiatric disorder via intermediary phenotypes by use of genetic first approaches in human studies and animal models need to take into account these complexities, and an endophenotype approach should be used cautiously. 50 Systems biology and network approaches are needed to capture the global architecture of genotype-phenotype associations, and efforts focusing on single causal pathways are likely to provide little research and clinical benefit.
Our study had several limitations. To take part in this study, individuals had to have a known genetic diagnosis, and so we did not capture data in any asymptomatic individuals who had ND-CNVs. Hence, the true phenotype in the general population is likely to be less severe than that reported here, with bias being increased for the ND-CNVs with a low penetrance. Some of our findings could have been influenced by ascertainment bias, because carriers with severe developmental delays are more likely to be referred to medical genetic clinics for testing; however, we found that the differences between ND-CNV carriers and controls remained significant after controlling for IQ. Due to our sample size, our analysis might be underpowered to detect more subtle genotypephenotype associations. Our findings for tic disorders and OCD should be treated cautiously because, due to the controls not meeting criteria for these conditions, Fisher's exact test had to be used to generate p values.
Our findings provide evidence of specific genotypephenotype associations in ND-CNV carriers, both in terms of quantitative and qualitative differences. However, these differences account for a low proportion of variance and therefore we believe that different genotypes do not result in discrete forms of neurodevelopmental disorders. Our approach of defining neurodevelopmental disorders using dimensional measures facilitated the investigation of genotype-phenotype associations beyond categorical psychiatric diagnosis. Using a multi-informant deepphenotyping approach, we found that genomic risk for psychiatric disorder had wide ranging effects on childhood development, spanning a range of cognitive and behavioural domains. Our findings highlight that core neurodevelopmental traits exist that are strongly impaired across all ND-CNV carriers, but ND-CNV carriers are also affected by broad ranging mental health and cognitive comorbidities. This broad range of impairments identified suggests that multiple processes and neural circuits are affected by ND-CNVs, and future research into the association between genotype and psychiatric outcomes via intermediary endophenotypes needs to consider the wide ranging pleiotropic effects of psychiatric genomic risk when interpreting their findings. Early identification of children with ND-CNVs is warranted to investigate antecedents and the develop mental course of neuropsychiatric impairments, add to the understanding of how genomic risk manifests, and inform early intervention programmes.
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